Hospices Civils De Lyon

The research program at Hospices Civils De Lyon concentrates on blood‑related and lymphatic disorders in children and young adults, testing innovative immunotherapies and targeted agents to enhance remission rates and long‑term survival.

• Classical Hodgkin lymphoma in children and young adults
• Relapsed/Refractory Aggressive Mature B-cell Neoplasms
• Pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Trials aim to evaluate safety, pharmacokinetics, and objective response, offering new therapeutic options for patients who have exhausted standard treatments.

Focused investigations address immune‑mediated complications of transplantation, including the prevention and treatment of acute graft‑versus‑host disease through advanced antibody preparations and novel small molecules.

• Steroid refractory Acute Graft versus host Disease
• Pediatric and adult patients undergoing HSC allograft procedures with Thymoglobulin® packaging

The studies characterize the pharmacokinetic profile of Thymoglobulin® and compare the efficacy of investigational agents such as MC0518 against best available therapy, seeking safer graft outcomes.

A broad oncology portfolio explores solid and hematologic cancers, integrating checkpoint inhibition and bispecific antibodies to improve response in hard‑to‑treat pediatric malignancies.

• Classical Hodgkin lymphoma in children and young adults
• Relapsed/Refractory Aggressive Mature B-cell Neoplasms
• Pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Research evaluates the safety and activity of agents like pembrolizumab and epcoritamab, aiming to establish new standards of care for patients with resistant disease.